PMDA drug package insert
リマチル錠50mg
PMDA Prescription drug · あゆみ製薬株式会社 · package insert Mar 17, 2026
Key facts
| Brand names | リマチル錠50mg, リマチル錠100mg |
|---|---|
| Nonproprietary names | ブシラミン |
| Companies | 製造販売元／あゆみ製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗リウマチ剤 |
| Therapeutic category codes | 874420 |
| YJ codes | 4420002F2059, 4420002F1117 |
| Approval numbers | 21400AMZ00492000, 21400AMZ00491000 |
| Package insert edition | 第2版 |
| Package insert date | Mar 17, 2026 |
| PMDA document key | 172190_4420002F1117_3 |
| PMDA company code | 172190 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: